Literature DB >> 20236211

Prognostic value of exercise myocardial scintigraphy in patients with coronary chronic total occlusions.

Alfredo R Galassi1, Gerald S Werner, Salvatore D Tomasello, Salvatore Azzarelli, Davide Capodanno, Giombattista Barrano, Francesco Marza', Luca Costanzo, Mariabarbara Campisano, Corrado Tamburino.   

Abstract

OBJECTIVES: To evaluate the prognostic value of exercise myocardial scintigraphy in patients undergoing incomplete revascularization by means of percutaneous coronary intervention (PCI) with at least a residual chronic total occlusion (CTO) left untreated.
METHODS: Of 569 consecutive patients with multivessel disease undergoing myocardial scintigraphy after incomplete revascularization by PCI between March 1997 and December 2004, 126 (79% male, 64+/-10 years) with >or= 1 residual CTO fulfilled the eligibility criteria and entered in the study. Hard events defined as cardiac death and myocardial infarction, soft events defined as incidence of unstable angina and PCI procedures, and their composite were assessed at a median follow-up period of 44 months.
RESULTS: Hard events were observed in six patients (4.8%). All of them had severely abnormal perfusion defects detected by myocardial scintigraphy. Soft events occurred in 0 (0%), 10 (7.9%), and 15 (11.9%) patients with normal, mildly abnormal, and severely abnormal perfusion, respectively. In the Kaplan-Meier analysis, the log-rank test was statistically significant across patients stratified by summed stress score either in terms of hard, soft and hard, or soft events. Univariate and multivariate Cox proportional-hazards showed an incremental significant information when the scintigraphic variables were added to clinical, angiographic, left ventricular ejection fraction, and Duke treadmill score, for prediction of the composite of hard and soft cardiac events (P < 0.006).
CONCLUSIONS: Among patients with a residual CTO left untreated after PCI, myocardial perfusion imaging provides significant independent information concerning the subsequent risk of cardiac events.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236211     DOI: 10.1111/j.1540-8183.2010.00527.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Prognosis of normal stress-only gated-SPECT myocardial perfusion imaging: a single center study.

Authors:  Maria João Vidigal Ferreira; Maria João Cunha; Anabela Albuquerque; Ana Paula Moreira; Domingos Ramos; Gracinda Costa; João Lima; Mariano Pego
Journal:  Int J Cardiovasc Imaging       Date:  2013-06-04       Impact factor: 2.357

2.  Percutaneous Treatment of Coronary Chronic Total Occlusions Part 1: Rationale and Outcomes.

Authors:  Alfredo Galassi; Aaron Grantham; David Kandzari; William Lombardi; Issam Moussa; Craig Thompson; Gerald Werner; Charles Chambers; Emmanouil Brilakis
Journal:  Interv Cardiol       Date:  2014-08

Review 3.  The indications and utility of adjunctive imaging modalities for chronic total occlusion (CTO) intervention.

Authors:  Usaid K Allahwala; Emmanouil S Brilakis; Hosen Kiat; Sally Ayesa; Daniel Nour; Michael Ward; Sidney Lo; James C Weaver; Ravinay Bhindi
Journal:  J Nucl Cardiol       Date:  2020-10-06       Impact factor: 5.952

4.  Role of Stress Myocardial Scintigraphy in the Evaluation of Incompletely Revascularized Post-PCI Patients.

Authors:  Alfredo R Galassi; Francesco Marzá; Salvatore Azzarelli; Salvatore D Tomasello
Journal:  Int J Mol Imaging       Date:  2011-09-21

5.  Recovery of myocardial perfusion after percutaneous coronary intervention of chronic total occlusions is comparable to hemodynamically significant non-occlusive lesions.

Authors:  Stefan P Schumacher; Roel S Driessen; Wijnand J Stuijfzand; Pieter G Raijmakers; Ibrahim Danad; Jo Dens; James C Spratt; Colm G Hanratty; Simon J Walsh; Ronald Boellaard; Albert C van Rossum; Maksymilian P Opolski; Alexander Nap; Paul Knaapen
Journal:  Catheter Cardiovasc Interv       Date:  2018-11-15       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.